A Red-Hot Tesla Burns Rubber on Consumer Reports
The Tesla Model S P85D sedan just broke the Consumer Reports rating system.
By definition, a car can’t exceed a score of 100 on the road test. But after the P85D racked up a score of 103, Consumer Reports was forced to create a new benchmark for the system and overhaul the ratings process according to a news release. The new system caused the car to slip to a score of 100.
A few characteristics of the car that allowed it to perform better in the test than any other car ever before include its rapid acceleration ability (0 to 60 mph in 3.5 seconds), its remarkable energy-efficiency (the car gets the equivalent of 87 miles per gallon) and its better breaking and handling system than the former top-scoring standard Model S. Two years ago, the base model version of the Model S received a 99 out of 100, which at the time was the highest rating ever for a vehicle.
Related: Why Americans Are Keeping Their Cars Longer Than Ever
The report is careful to note that even with a perfect score, the Tesla isn’t a perfect car. Besides a price tag of $127,820, beyond the means of the average person and the most expensive car Consumer Reports has ever reviewed, the car is louder than the base Model S and isn’t as plush as other luxury vehicles.
In addition, a long drive might be problematic if there aren’t any nearby charging stations along the route due to the vehicle’s 200-plus mile range. The rating also doesn’t account for the Tesla’s reliability, but the Model S comes with average reliability, according to owner-survey responses.
Imperfections aside, the car received an enviable final assessment. “It’s a remarkable car that paves a new, unorthodox course, and it’s a powerful statement of American startup ingenuity,” the report reads.
Tax Refunds Rebound
Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years.
Number of the Day: $22 Trillion
The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.
Chart of the Week: The Soaring Cost of Insulin
The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494.
Chart of the Day: Shutdown Hits Like a Hurricane
The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said.
Chart of the Week: Lowering Medicare Drug Prices
The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.
In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.
